|開催日時：||2019年7月30日 17：00 ～ 18：00|
|講師：||Robert M. Hoffman|
|所属：||Professor・Department of Surgery, University of California, San Diego Medical Center
President, Chairman of Board and CEO・AntiCancer, Inc.
CEO・Robert M. Hoffman Foundation for Cancer Research
|演題：||Targeting the general cancer metabolic defect of methionine addiction with recombinant methioninase in patient-derived orthotopic xenograft (PDOX) mouse models|
It has been known for 60 years since Sugimura’s first observation that tumors have a specific and elevated dependence on methionine. Our laboratory showed in the 1970s and 1980s that cancer dependence on methionine is do the elevated flux of methionine in cancer cells due to abnormally high levels of trans-methylation reactions. Methionine restriction of cancer cells results in severe depletion of methionine and S-adenosylmethionine and cancer-selective arrest in the S-phase of the cell cycle. Our laboratory developed the bacterial enzyme methioninase to target methionine addiction of cancer cells and recently found that methioninase can be effectively delivered orally in patient- derived orthotopic xenograft (PDOX) mouse models. Methioninase alone and in combination with chemotherapy was highly effective in PDOX models of sarcoma, pancreatic cancer, melanoma and colon cancer, suggesting a high potential of methioninase in the clinic.
|世話人：||〇谷 憲三朗 （ALA先端医療学社会連携研究部門）
井上 純一郎 （分子発癌分野）